
News|Videos|September 21, 2023
CHRYSALIS-2: Amivantamab + Lazertinib in Non–Small Cell Lung Cancer
Key opinion leaders review data from the CHRYSALIS-2 trial and consider the optimal utilization of amivantamab and lazertinib in combination in the setting of non–small cell lung cancer management.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5






































